Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo

Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat

(2010) E. Sebokova et al.   DIABETES OBESITY & METABOLISM

Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability andin VivoPotency

(2010) Elena Sebokova et al.   ENDOCRINOLOGY

Determination of Taspoglutide in Human and Animal Plasma Using Liquid Chromatography−Tandem Mass Spectrometry with Orthogonal Column-Switching

(2009) Katja Heinig et al.   ANALYTICAL CHEMISTRY

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

(2009) M. A. Nauck et al.   DIABETES CARE

GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival

(2008) J. Buteau   DIABETES & METABOLISM

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

(2008) T. Vilsbøll et al.   DIABETIC MEDICINE

Glucagon-like Peptide-1 Activation of TCF7L2-dependent Wnt Signaling Enhances Pancreatic Beta Cell Proliferation

(2008) Zhengyu Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY